What is Parkinson's Disease Drugs Market?
According to the American Association of Neurological Surgeons, in the United States, around 60,000 new cases of Parkinson’s disease are diagnosed each year and one to 1.5 million Americans currently have the disease. Parkinson's disease is a progressive nervous system disorder caused by degeneration of nerve cells in the part of the brain called the substantia nigra that affects movement. Recent studies have shown that symptoms of Parkinson's develop in patients with an 80 percent or greater loss of dopamine-producing cells in the substantia nigra. There is currently no cure for the disease, but treatment can help to relieve the symptoms and maintain the patient's quality of life.
The market study is being classified by Type (Carbidopa/Levodopa, Dopamine Receptor Agonists and MAO-Inhibitors) and major geographies with country level break-up.
AbbVie (United States, Merck (United States), Boehringer Ingelheim (Germany), Teva (Israel), Novartis AG (Switzerland), GSK (United Kingdom), Impax Laboratories (United States), Lundbeck (Denmark), UCB (Belgium), Valeant Pharmaceuticals (Canada), Acadia (United States), Sun Pharma (India), Wockhardt (India), Dr. Reddy’s (India), Intas (India), US WorldMeds (United States), Zydus Cadila (India) and Cipla (India) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Strides (India), 1 A Pharma (India) and Upsher-Smith (United States).
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Parkinson's Disease Drugs market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Parkinson's Disease Drugs market by Type, Application and Region.
On the basis of geography, the market of Parkinson's Disease Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Prevalence of Parkinson's Disease among Elderly People
- High Demand for Effective Treatment for Parkinson's Disease
- Increased Research and Development Activities
- Rise in the Number of Diagnostic Centres
- No Complete Cure of Parkinson's Disease Available
- Growth in the Geriatric Population Worldwide
- Growth in the Healthcare Sector
- Stringent Government Rules and Regulations
Key Target AudienceParkinson's Disease Drugs Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies, Research Professionals and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase